Literature DB >> 22027703

The effect of a single oral megadose of vitamin D provided as either ergocalciferol (D₂) or cholecalciferol (D₃) in alcoholic liver cirrhosis.

Mikkel Malham1, Søren Peter Jørgensen, Anna L Lauridsen, Peter Ott, Henning Glerup, Jens F Dahlerup.   

Abstract

OBJECTIVE: The goal of this study was to examine the effects of a single oral dose of 300,000 international units of either ergocalciferol (D₂) or cholecalciferol (D₃) on the plasma levels of 25-hydroxyvitamin D in patients with alcoholic liver cirrhosis.
METHODS: Inclusion criteria for this study were diagnosis of alcoholic liver cirrhosis and plasma levels of 25-hydroxyvitamin D less than 25 nmol/l. At baseline, patients were divided into Child-Pugh groups A, B, or C and were given one oral dose of 300,000 international units of ergocalciferol (D₂ group, N=23) or cholecalciferol (D₃ group, N=13). Plasma concentrations of 25(OH) vitamin D and vitamin D-binding protein were measured on days 0, 7, 30, and 90.
RESULTS: On days 7 and 30, patients from the D₃ group had higher vitamin D levels than patients from the D₂ group (P<0.05). On day 7, vitamin D levels were found to correlate with Child-Pugh scores from patients in the D₃ group. For patients in the D₂ group, there was a positive correlation between vitamin D and vitamin D-binding protein as indicated by the area under the concentration versus time curves (Spearmen's ρ=0.64 P<0.001).
CONCLUSION: In patients with alcoholic liver cirrhosis, a single oral megadose of cholecalciferol was more effective than ergocalciferol in the treatment of vitamin D deficiency. Severe liver disease and low levels of vitamin D-binding protein were predictors for poor treatment outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22027703     DOI: 10.1097/MEG.0b013e32834d1755

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

Review 1.  Vitamin D supplementation for chronic liver diseases in adults.

Authors:  Milica Bjelakovic; Dimitrinka Nikolova; Goran Bjelakovic; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2021-08-25

2.  Status of research on vitamin D supplementation in treating or preventing liver fibrosis.

Authors:  Byoung-Joon Song; Don C Rockey
Journal:  Liver Int       Date:  2013-05       Impact factor: 5.828

Review 3.  Large, single-dose, oral vitamin D supplementation in adult populations: a systematic review.

Authors:  Malcolm D Kearns; Jessica A Alvarez; Vin Tangpricha
Journal:  Endocr Pract       Date:  2014-04       Impact factor: 3.443

4.  Effects of Vitamin D Supplementation on Serum 25-Hydroxyvitamin D Concentrations in Cirrhotic Patients: A Randomized Controlled Trial.

Authors:  Stefan Pilz; Csilla Putz-Bankuti; Martin Gaksch; Walter Spindelboeck; Marius Haselberger; Florian Rainer; Andreas Posch; Philipp Kreuzer; Tatjana Stojakovic; Vanessa Stadlbauer; Barbara Obermayer-Pietsch; Rudolf E Stauber
Journal:  Nutrients       Date:  2016-05-10       Impact factor: 5.717

5.  Serum 25-hydroxyvitamin D levels and mortality risk in patients with liver cirrhosis: a protocol for a systematic review and meta-analysis of observational studies.

Authors:  Désirée Völker; Frank Grünhage; Stefan Wagenpfeil; Frank Lammert; Caroline S Stokes
Journal:  Syst Rev       Date:  2019-03-23

Review 6.  Role of Vitamin D in Liver Disease and Complications of Advanced Chronic Liver Disease.

Authors:  Federico Ravaioli; Alessandra Pivetti; Lorenza Di Marco; Christou Chrysanthi; Gabriella Frassanito; Martina Pambianco; Chiara Sicuro; Noemi Gualandi; Tomas Guasconi; Maddalena Pecchini; Antonio Colecchia
Journal:  Int J Mol Sci       Date:  2022-08-12       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.